Most shots go into your arm, but germs enter through your nose. This project is building a way to deliver vaccines directly into the nose to stop germs before they even get a foothold. It's like putting a security guard at the front door instead of trying to catch a thief once they are already inside the house.
Current respiratory vaccines are injected into muscles, which fails to stop germs from colonizing the nose and throat. This allows pathogens to continue spreading even in vaccinated populations.
Nasal delivery formulations for RNA and protein antigens, and specific vaccine candidates targeting S. pneumoniae, B. pertussis, influenza, and SARS-CoV-2.
If you are a vaccine manufacturer dealing with low efficacy in preventing transmission of COVID-19 and flu — this project developed nasal delivery formulations for RNA and protein antigens that block infection at the earliest stage.
If you are a drug delivery specialist dealing with the challenge of mucosal immunity — this project developed nasal vaccine platforms that target S. pneumoniae and B. pertussis to prevent upper respiratory tract colonization.
If you are a health agency dealing with high morbidity from respiratory outbreaks — this project developed a bivalent nasal vaccine to simultaneously prevent influenza and COVID-19, reducing the need for multiple injections.
Based on available project data, there is no information regarding the cost or pricing of the vaccine candidates.
The project focuses on developing formulations and candidates; based on available project data, industrial scaling details are not yet provided.
Based on available project data, specific patent or licensing terms are not mentioned, though the project aims to enrich the pipeline for novel vaccines.
The project runs from 2023-05-01 to 2028-04-30, suggesting that candidates will be developed and evaluated within this window.
The project specifically addresses the acceptability of nasal vaccination to ensure it can be integrated into public health strategies.
The consortium is research-heavy, consisting of 14 partners across 9 countries. With 6 universities and 5 research institutes, the focus is on discovery, but a 21% industry ratio (including 3 industry partners and 2 SMEs) ensures that the transition from lab to product is considered.
Contact the European Vaccine Initiative (EVI) in Germany.
Contact us to track the development of these nasal vaccine candidates for your portfolio.
